HEOR

AJMC 9 April 2025 by Pearl Steinzor and Laura Bobolts Commentary and video Laura Bobolts, PharmD, BCOP, senior vice president of clinical...

Nature 17 April 2025 Standard treatment for symptomatic myelofibrosis (MF) patients includes JAK inhibitors (JAKi) like ruxolitinib and...

Commentary | Video : UROToday 26 March 2025 Neeraj Agarwal speaks with Hannah McManus about research from the IRONMAN registry examining...

The way ahead for HEOR in biopharma should be built on increasing C-suite visibility and understanding of the value contribution that HEOR makes and demonstrating that a failure to invest in HEOR puts companies at a competitive disadvantage, especially in the face of rising regulatory and payer expectations for evidence.